Daiichi Sankyo says Sun Pharma to buy Indian unit Ranbaxy
TOKYO (Reuters) - Japan's Daiichi Sankyo Co Ltd (4568.T) said on Monday Sun Pharmaceutical Industries Ltd (SUN.NS) will buy its Indian unit Ranbaxy Laboratories Ltd (RANB.NS), creating the world's fifth-largest speciality generics company.
Daiichi Sankyo said in a statement that it agrees to vote its shares in Ranbaxy in favour of the acquisition through a share swap.
It said Ranbaxy shareholders will get 0.8 Sun Pharma shares for each Ranbaxy share. The merged company will also become the largest drug firm in India.
(Reporting by Dominic Lau; Editing by Stephen Coates)
- Tweet this
- Share this
- Digg this
- Iran to push for Saudi oil output cut at OPEC - Mehr news agency
- Aviva falls on Friends Life merger plan doubts |
- Aviva, Friends Life 5.6 billion pound merger plan makes sense - investors
- Putin says Russia not isolated over Ukraine, blames West for frosty ties
- Tesla says in talks with BMW over car batteries, parts